Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis
Shots:
- Both P-III (INTEGUMENT-1) & (INTEGUMENT-2) trials evaluate the safety and efficacy of Zoryve Cream (0.15%) vs vehicle in patients with Atopic Dermatitis. The results from the study were presented at WCDC 2024
- From the pooled analysis of both studies at wk4 the results from the study depicted a 50% reduction in EASI-50 by 69.2% vs 44.4% of patients, a 75% reduction in EASI-75 by 44.5% vs 21.2%, a reduction in EASI-90 by 22.4% vs 8.6% & a 100% reduction in EASI-100 by 9.8% vs 4.8% of patients. As per the results 85% of patients achieved measurable improvement by wk1
- Zoryve (roflumilast) cream is a topical phosphodiesterase-4 (PDE4) inhibitor that has been approved by the US FDA for the topical treatment of plaque psoriasis (aged 6 & above)
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
